Wealthquest Corp Invests $1.04 Million in Moderna, Inc. (NASDAQ:MRNA)

Wealthquest Corp purchased a new position in Moderna, Inc. (NASDAQ:MRNA) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 36,587 shares of the company’s stock, valued at approximately $1,037,000.

Several other institutional investors have also recently made changes to their positions in the company. Asset Management One Co. Ltd. increased its holdings in shares of Moderna by 5.9% in the first quarter. Asset Management One Co. Ltd. now owns 130,325 shares of the company’s stock worth $3,695,000 after purchasing an additional 7,274 shares during the period. Kentucky Retirement Systems Insurance Trust Fund bought a new position in Moderna in the first quarter valued at $266,000. Praxis Investment Management Inc. increased its stake in Moderna by 110.5% in the first quarter. Praxis Investment Management Inc. now owns 16,710 shares of the company’s stock valued at $474,000 after acquiring an additional 8,770 shares during the last quarter. Rakuten Securities Inc. increased its stake in Moderna by 248.8% in the first quarter. Rakuten Securities Inc. now owns 26,160 shares of the company’s stock valued at $742,000 after acquiring an additional 18,661 shares during the last quarter. Finally, QRG Capital Management Inc. increased its stake in Moderna by 16.1% in the first quarter. QRG Capital Management Inc. now owns 8,274 shares of the company’s stock valued at $235,000 after acquiring an additional 1,150 shares during the last quarter. Institutional investors own 75.33% of the company’s stock.

Moderna Trading Up 4.4%

Moderna stock opened at $26.80 on Wednesday. The firm has a 50-day moving average of $26.27 and a 200-day moving average of $32.14. The firm has a market cap of $10.36 billion, a P/E ratio of -3.07 and a beta of 1.86. Moderna, Inc. has a 1-year low of $23.15 and a 1-year high of $138.07.

Moderna (NASDAQ:MRNA) last posted its earnings results on Thursday, May 1st. The company reported ($2.52) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.92) by $0.40. The company had revenue of $108.00 million during the quarter, compared to analyst estimates of $130.35 million. Moderna had a negative net margin of 105.67% and a negative return on equity of 28.69%. Moderna’s revenue for the quarter was down 35.3% on a year-over-year basis. During the same period in the prior year, the business posted ($3.07) earnings per share. Research analysts forecast that Moderna, Inc. will post -9.61 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

MRNA has been the topic of a number of research analyst reports. William Blair reissued a “market perform” rating on shares of Moderna in a research note on Monday, June 2nd. UBS Group reduced their target price on Moderna from $78.00 to $70.00 and set a “buy” rating on the stock in a research note on Friday, May 2nd. Evercore ISI reduced their target price on Moderna from $50.00 to $32.00 and set an “in-line” rating on the stock in a research note on Friday, May 2nd. Citigroup initiated coverage on Moderna in a research note on Thursday, March 13th. They issued a “neutral” rating and a $40.00 target price on the stock. Finally, Morgan Stanley reduced their target price on Moderna from $39.00 to $32.00 and set an “equal weight” rating on the stock in a research note on Wednesday, April 9th. Four equities research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Moderna currently has a consensus rating of “Hold” and an average price target of $46.61.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.